Clinical Research Directory
Browse clinical research sites, groups, and studies.
Back to Studies
NOT YET RECRUITING
NCT07615101
PHASE3
Open-label, Phase 3, Multi Center, Single-arm, Imaging Study Investigating the Safety and Diagnostic Performance of 68Ga-NYM032 Injection PET/CT in Men With Newly Diagnosed Prostate Cancer.
Sponsor: Norroy Bioscience Co., LTD
View on ClinicalTrials.gov
Summary
The investigators are imaging patients with newly diagnosed prostate cancer using a new Positron Emission Tomography (PET) imaging agent (68Ga-NYM032) in order to evaluate the safety and diagnostic performance.
Key Details
Gender
FEMALE
Age Range
18 Days - Any
Study Type
INTERVENTIONAL
Enrollment
365
Start Date
2026-06-01
Completion Date
2027-07-30
Last Updated
2026-05-29
Healthy Volunteers
No
Conditions
Interventions
DRUG
68-Ga-NYM032
IV injection